

eCAP Episode of Care Assurance Program

A partnership peerless in our industry



Why should eCAP be important to my hospital?

Our healthcare providers are being challenged in new ways today:

- CJR ruling
- Move to Bundled Payment for Care Improvement (BPCI), Readmission Reduction Program (HRRP)
- The average cost of a readmission after lower extremity joint reconstruction exceeds \$16,000*
 This means healthcare providers must strive to prevent unplanned readmissions

How does eCAP work?

Once enrolled in the program, each patient receiving a Smith & Nephew primary joint reconstruction, will also use a PICO Single Use Negative Pressure Wound Therapy device and an ACTICOAT Flex 7 Antimicrobial Barrier Dressing on the closed surgical incision. If any patient enrolled in the program is readmitted with an infection at the surgery site or to revise the implant as a result of the failure of the implant, the PICO system or the ACTICOAT Flex 7 dressing to work as expected (consistent with the products labeling), then Smith & Nephew will refund to the hospital its unreimbursed costs for the readmission up to the aggregate purchase price of the implant, PICO system and ACTICOAT Flex 7 dressing.

A written agreement is required to execute the eCAP program, please contact your Smith & Nephew representative for more details.

Reference 1 - PICO° Negative Pressure Wound Therapy

The PICO Single Use Negative Pressure Wound Therapy System consists of a pump and two sterile dressing kits. The PICO pump maintains negative pressure wound therapy (NPWT) at 80mmHg (nominal) +/-20 mmHg to the wound surface. Exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film. PICO is intended for use in wound sizes (surface area x depth) up to 400cc which are considered to be low to moderately exuding. The kit is intended to be used for a maximum of 7 days on low exuding wounds and 6 days on moderately exuding wounds. Therapy duration of the kit may be less than indicated if clinical practice or other factors such as wound type, wound size, rate or volume of exudate, orientation of the dressing or environmental conditions, result in more frequent dressing changes.

Indications for Use

PICO Negative Pressure Wound Therapy System is indicated for patients who would benefit from a suction device (negative pressure wound therapy) as it may promote wound healing via removal of low to moderate levels of exudate and infectious materials. Examples of appropriate wound types include:

- Chronic
- Acute
- Traumatio
- Subacute and dehisced wounds
- Partial-thickness burns
- Ulcers (such as diabetic or pressure)
- Flaps and grafts
- Closed surgical incisions

PICO Single Use Negative Pressure Wound Therapy System is suitable for use both in a hospital and homecare setting.

Contraindications

The use of PICO is contraindicated in the presence of:

- Patients with malignancy in the wound bed or margins of the wound (except in palliative care to enhance quality of life)
- · Previously confirmed and untreated osteomyelitis
- Non-enteric and unexplored fistulas
- Necrotic tissue with eschar present
- · Exposed arteries, veins, nerves or organs
- · Anastomotic sites
- · Emergency airway aspiration
- Pleural, mediastinal or chest tube drainage
- Surgical suction

Reference 2 - ACTICOAT° Flex 7 Dressings

The ACTICOAT Flex 7 dressing consists of a flexible, low adherent polyester layer coated with nanocrystalline silver. The ACTICOAT Flex 7 is a highly confortable dressing. Nanocrystalline silver provides an effective barrier to microbial contamination. The antimicrobial barrier properties of the ACTICOAT Flex 7 dressings remain effective for up to 7 days. The antimicrobial barrier properties and the ability of the dressing to allow fluid to pass through without impairment, (*in vitro data*) has shown ACTICOAT Flex 7 to be compatible with negative pressure wound therapy (NPWT) for a period of up to 3 days. ACTICOAT Flex 7 is not intended to provide sole treatment for infected wounds. ACTICOAT Flex 7 may be used on infected wounds which are being managed per local clinical protocol. The dressing is low adherent, which helps to minimize wound trauma at dressing changes. The silver coating is derived from a silver target which is 99.99% silver. The coating which is applied to the dressing is predominantly silver with a small number of oxygen atoms trapped within the coating structure. The coatings are highly porous and consist of equiaxed nanocrystals organized into coarse columnar structures. These unique physical structures, in combination with the oxygen atoms/molecules that are trapped in the crystal lattice, contribute to the enhanced solubility of the films.

Indications for Use

ACTICOAT Flex 7 dressing is indicated for use on partial and full thickness wounds for up to 7 days. This includes: first and second-degree burns, as a protective covering of grafts, surgical sites, venous ulcers, pressure ulcers and diabetic ulcers.

Reference 3 - Average cost of readmission

Medicare FFS Part A and B Breakdown of Cost Across Care Continuum THA (2011-2013).

Contraindications

- Do not use on patients with a known sensitivity to silver.
- Do not use on patients during MRI (Magnetic Resonance Imaging) examination.
- Prior to administering radiation therapy, remove ACTICOAT Flex 7.
 A new dressing can be applied following each treatment.

For detailed product information, including indications for use, contraindications, effects, precautions and warnings, please consult each product's Instructions for Use (IFU) prior to use.

Supporting healthcare professionals for over 150 years

Smith & Nephew, Inc. 7135 Goodlett Farms Parkway Cordova, TN 38016 USA www.smith-nephew.com

Wound Management Smith & Nephew Medical Ltd 101 Hessle Road Hull HU3 2BN

Telephone: 1-901-396-2121 Information: 1-800-821-5700 Orders and Inquiries: 1-800-238-7538